Inflammatory bowel disease alters intestinal bile acid transporter expression

Drug Metabolism and Disposition

Volumn 42, Issue 9, 2014, Pages 1423-1431

  Jahnel, Jörg ^a   Fickert, Peter ^a   Hauer, Almuthe C ^a   Hog̈enauer, Christoph ^a   Avian, Alexander ^a   Trauner, Michael ^a,b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; BILE ACID BINDING PROTEINS; CARRIER PROTEIN; CELL RECEPTOR; COTRANSPORTER; MEMBRANE PROTEIN; MESSENGER RNA; ORGANIC ANION TRANSPORTER; SODIUM-BILE ACID COTRANSPORTER;

ADULT; BIOPSY; CASE CONTROL STUDY; COLON; DOWN REGULATION; FEMALE; GENETICS; HUMAN; ILEUM; INFLAMMATORY BOWEL DISEASE; MALE; METABOLISM; MIDDLE AGED; PROCEDURES; ULCERATIVE COLITIS;

ADULT; BILE ACIDS AND SALTS; BIOPSY; CARRIER PROTEINS; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; COLON; DOWN-REGULATION; FEMALE; HUMANS; ILEUM; INFLAMMATORY BOWEL DISEASES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; SYMPORTERS;

EID: 84906860292     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.058065     Document Type: Article

References (55)

1. Alnouti Y (2009) Bile Acid sulfation: a pathway of bile acid elimination and detoxification. Toxicol Sci 108:225-246.
2. Beigneux AP, Moser AH, Shigenaga JK, Grunfeld C, and Feingold KR (2000) The acute phase response is associated with retinoid X receptor repression in rodent liver. J Biol Chem 275:16390-16399. (Pubitemid 30366957)
3. Claudel T, Zollner G, Wagner M, and Trauner M (2011) Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease. Biochim Biophys Acta 1812:867-878.
4. Corazza GR, Ciccarelli R, Caciagli F, and Gasbarrini G (1979) Cyclic AMP and cyclic GMP levels in human colonic mucosa before and during chenodeoxycholic acid therapy. Gut 20:489-492. (Pubitemid 9209000)
5. Dawson PA, Haywood J, Craddock AL, Wilson M, Tietjen M, Kluckman K, Maeda N, and Parks JS (2003) Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J Biol Chem 278:33920-33927. (Pubitemid 37553226)
6. Ejderhamn J, Rafter JJ, and Strandvik B (1991) Faecal bile acid excretion in children with inflammatory bowel disease. Gut 32:1346-1351.
7. Gadaleta RM, Oldenburg B, Willemsen EC, Spit M, Murzilli S, Salvatore L, Klomp LW, Siersema PD, van Erpecum KJ, and van Mil SW (2011a) Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-kB signaling in the intestine. Biochim Biophys Acta 1812:851-858.
8. Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LW, Siersema PD, Schipper ME, and Danese S, et al. (2011b) Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60:463-472.
9. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, and Sandborn WJ, et al. (2000) A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 6:8-15.
10. Geier A, Dietrich CG, Voigt S, Ananthanarayanan M, Lammert F, Schmitz A, Trauner M, Wasmuth HE, Boraschi D, and Balasubramaniyan N, et al. (2005) Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. Am J Physiol Gastrointest Liver Physiol 289:G831-G841. (Pubitemid 41532576)
11. Gnewuch C, Liebisch G, Langmann T, Dieplinger B, Mueller T, Haltmayer M, Dieplinger H, Zahn A, Stremmel W, and Rogler G, et al. (2009) Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. World J Gastroenterol 15:3134-3141.
12. Greig ER, Boot-Handford RP, Mani V, and Sandle GI (2004) Decreased expression of apical Na+ channels and basolateral Na+, K+-ATPase in ulcerative colitis. J Pathol 204:84-92. (Pubitemid 39214485)
13. Ho RH, Leake BF, Urquhart BL, Gregor JC, Dawson PA, and Kim RB (2011) Functional characterization of genetic variants in the apical sodium-dependent bile acid transporter (ASBT; SLC10A2). J Gastroenterol Hepatol 26:1740-1748.
14. Hofmann AF (1999) The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 159:2647-2658.
15. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, and Richardson JA, et al. (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2:217-225.
16. Ishiguro Y (1999) Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol 34:66-74.
17. Jung D, Fantin AC, Scheurer U, Fried M, and Kullak-Ublick GA (2004) Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor. Gut 53:78-84. (Pubitemid 38083014)
18. Keating N, Mroz MS, Scharl MM, Marsh C, Ferguson G, Hofmann AF, and Keely SJ (2009) Physiological concentrations of bile acids down-regulate agonist induced secretion in colonic epithelial cells. J Cell Mol Med 13 (8B):2293-2303.
19. Kim MS, Shigenaga J, Moser A, Feingold K, and Grunfeld C (2003) Repression of farnesoid X receptor during the acute phase response. J Biol Chem 278:8988-8995. (Pubitemid 36800376)
20. Kolios G, Valatas V, and Ward SG (2004) Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology 113:427-437. (Pubitemid 39593361)
21. Kullak-Ublick GA, Stieger B, and Meier PJ (2004) Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 126:322-342. (Pubitemid 38040747)
22. Kwon RS and Carey MC (2004) Do steroids ameliorate bile acid malabsorption in Crohn's disease? Gut 53:10-11. (Pubitemid 38083003)
23. Landrier JF, Grober J, Zaghini I, and Besnard P (2002) Regulation of the ileal bile acid-binding protein gene: an approach to determine its physiological function(s). Mol Cell Biochem 239:149-155. (Pubitemid 35385805)
24. Langmann T, Moehle C, Mauerer R, Scharl M, Liebisch G, Zahn A, Stremmel W, and Schmitz G (2004) Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 127:26-40. (Pubitemid 38962271)
25. Lenicek M, Duricova D, Komarek V, Gabrysova B, Lukas M, Smerhovsky Z, and Vitek L (2011) Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. Inflamm Bowel Dis 17:1322-1327.
26. Luo G, Guenthner T, Gan LS, and Humphreys WG (2004) CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr Drug Metab 5:483-505. (Pubitemid 39534494)
27. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, and Shan B (1999) Identification of a nuclear receptor for bile acids. Science 284:1362-1365. (Pubitemid 29289663)
28. Meihoff WE and Kern F, Jr (1968) Bile salt malabsorption in regional ileitis, ileal resection and mannitol-induced diarrhea. J Clin Invest 47:261-267.
29. Moore LB, Parks DJ, Jones SA, Bledsoe RK, Consler TG, Stimmel JB, Goodwin B, Liddle C, Blanchard SG, and Willson TM, et al. (2000) Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 275:15122-15127. (Pubitemid 30337234)
30. Mroz MS, Keating N, Ward JB, Sarker R, Amu S, Aviello G, Donowitz M, Fallon PG, and Keely SJ (2013) Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo. Gut 63:808-817.
31. Neimark E, Chen F, Li X, and Shneider BL (2004) Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology 40:149-156. (Pubitemid 38877576)
32. Nijmeijer RM, Gadaleta RM, van Mil SW, van Bodegraven AA, Crusius JB, Dijkstra G, Hommes DW, de Jong DJ, Stokkers PC, and Verspaget HW, et al.; Dutch Initiative on Crohn, Colitis (ICC) (2011) Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease. PLoS ONE 6:e23745.
33. Nolan JD, Johnston IM, and Walters JR (2013) Altered enterohepatic circulation of bile acids in Crohn's disease and their clinical significance: a new perspective. Expert Rev Gastroenterol Hepatol 7:49-56.
34. Oelkers P, Kirby LC, Heubi JE, and Dawson PA (1997) Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J Clin Invest 99:1880-1887. (Pubitemid 27175935)
35. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, and Moore DD, et al. (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284:1365-1368. (Pubitemid 29289664)
36. Raddatz D, Bockemühl M, and Ramadori G (2005) Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 17:547-557. (Pubitemid 40592713)
37. Renner O, Harsch S, Schaeffeler E, Winter S, Schwab M, Krawczyk M, Rosendahl J, Wittenburg H, Lammert F, and Stange EF (2009) A variant of the SLC10A2 gene encoding the apical sodium-dependent bile acid transporter is a risk factor for gallstone disease. PLoS ONE 4:e7321.
38. Roberts MS, Magnusson BM, Burczynski FJ, and Weiss M (2002) Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41:751-790. (Pubitemid 34948196)
39. Rogler G and Andus T (1998) Cytokines in inflammatory bowel disease. World J Surg 22:382-389. (Pubitemid 28113526)
40. Rutgeerts P, Ghoos Y, and Vantrappen G (1979) Bile acid studies in patients with Crohn's colitis. Gut 20:1072-1077. (Pubitemid 10183260)
41. Sands BE (2007) Inflammatory bowel disease: past, present, and future. J Gastroenterol 42: 16-25.
42. Saverymuttu SH, Hodgson HJ, Chadwick VS, and Pepys MB (1986) Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 27:809-813. (Pubitemid 16058500)
43. Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, Lamba J, Kim RB, Ramachandran V, and Komoroski BJ, et al. (2001) Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem 276:39411-39418. (Pubitemid 37371319)
44. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K et al.(2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19 (Suppl A):5A-36A.
45. Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, Feakins R, Fléjou JF, Herfarth H, and Hommes DW, et al.; European Crohn's and Colitis Organisation (ECCO) (2008) European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohn's Colitis 2:1-23. (Pubitemid 351179487)
46. Sullivan S, Alex P, Dassopoulos T, Zachos NC, Iacobuzio-Donahue C, Donowitz M, Brant SR, Cuffari C, Harris ML, and Datta LW, et al. (2009) Downregulation of sodium transporters and NHERF proteins in IBD patients and mouse colitis models: potential contributors to IBD-associated diarrhea. Inflamm Bowel Dis 15:261-274.
47. Sundaram U, Wisel S, Stengelin S, Kramer W, and Rajendran V (1998) Mechanism of inhibition of Na+-bile acid cotransport during chronic ileal inflammation in rabbits. Am J Physiol 275:G1259-G1265.
48. Torres J, Pineton de Chambrun G, Itzkowitz S, Sachar DB, and Colombel JF (2011) Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther 34:497-508.
49. Tougaard L, Giese B, Pedersen BH, and Binder V (1986) Bile acid metabolism in patients with Crohn's disease in terminal ileum. Scand J Gastroenterol 21:627-633. (Pubitemid 16085655)
50. Trauner M and Boyer JL (2003) Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 83:633-671. (Pubitemid 36378680)
51. Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkühn T, Orchard T, Rogler G, and Louis E, et al.; European Crohn's and Colitis Organisation (ECCO) (2010) The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohn's Colitis 4:7-27.
52. Vavassori P, Mencarelli A, Renga B, Distrutti E, and Fiorucci S (2009) The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 183:6251-6261.
53. Vermeire S, Van Assche G, and Rutgeerts P (2006) Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 55:426-431. (Pubitemid 43268284)
54. Walters JR, Tasleem AM, Omer OS, Brydon WG, Dew T, and le Roux CW (2009) A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 7:1189-1194.
55. Wojtal KA, Eloranta JJ, Hruz P, Gutmann H, Drewe J, Staumann A, Beglinger C, Fried M, Kullak-Ublick GA, and Vavricka SR (2009) Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients. Drug Metab Dispos 37:1871-1877.